Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
Status:
Completed
Trial end date:
2012-10-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at measures that will help scientists understand the way
Omalizumab, an FDA-approved anti-allergy medication, works.